You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK)與微境生物簽署技術轉讓及合作協議
格隆匯 09-16 19:58

格隆匯9月16日丨君實生物(01877.HK)公告,公司擬與微境生物醫藥科技(上海)有限公司("微境生物")簽署《技術轉讓及合作協議》("協議"),微境生物將其研發的四款藥物項目代號分別為WJ1024/WJ1075(以公司最終選定的其中一為準)、WJ05129、APL1898、WJ13404的50%權益轉讓給公司,公司將獲得上述藥物在全球範圍內的獨家生產權、委託生產權及銷售權。

雙方將按照協議共同推進上述藥物的臨牀前研究工作,公司將負責進行臨牀實驗申請,臨牀試驗的後續開展及藥品註冊申請和上市銷售許可等事宜由雙方共同設立的聯合指導委員會確定。

一、WJ1024/WJ1075(以公司最終選定的其中一為準),一種基於共價抑制劑特徵設計開發的抑制XPO1蛋白的、快速代謝的口服廣譜抗腫瘤小分子藥物,臨牀可用於多種血液瘤和實體瘤。二、WJ05129,一種口服小分子AuroraA抑制劑。AuroraA抑制劑與RB1基因缺失或失活具有合成致死的效果,可以用於治療小細胞肺癌和三陰乳腺癌等RB1缺失或失活的惡性腫瘤。

三、APL1898,一種有效抑制EGFR-exon20插入變異的靶向小分子抑制劑。臨牀前數據顯示該藥物分子保持了抑制T790M等EGFR常見變異的活性,但同時克服了第三代EGFR抑制劑對exon20插入變異的不敏感。

四、WJ13404,一種有效的第四代EGFR抑制劑。臨牀前數據顯示該藥物分子對包括Del19/T790M/C797S和L858R/T790M/C797S在內的,對第三代EGFR抑制劑不敏感的獲得性EGFR變異有很好的抑制活性,同時對野生型EGFR具有高度選擇性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account